Stay updated on Nivolumab Combo in BCG Unresponsive Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combo in BCG Unresponsive Bladder Cancer Clinical Trial page.

Latest updates to the Nivolumab Combo in BCG Unresponsive Bladder Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedMinor revision update from v3.4.1 to v3.4.2; no user-facing content or functionality changes were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedThe page now displays Revision: v3.4.1 (replacing v3.4.0). This is a minor metadata update that does not affect study data, eligibility criteria, or locations.SummaryDifference0.0%

- Check33 days agoChange DetectedGlossary visibility controls (Show/Hide glossary) were added and the page now displays updated metadata labels such as 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check41 days agoChange DetectedPage revision label updated from v3.3.3 to v3.3.4, a minor metadata change with no impact on study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check69 days agoChange DetectedNumerous new study sites were added across the US and worldwide and several existing sites were removed, changing where participants can enroll.SummaryDifference3%

- Check90 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2.SummaryDifference0.0%

Stay in the know with updates to Nivolumab Combo in BCG Unresponsive Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo in BCG Unresponsive Bladder Cancer Clinical Trial page.